# African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translation

> **NIH NIH U54** · NORTHWESTERN UNIVERSITY · 2020 · $68,803

## Abstract

Pharmacogenomics research holds the promise of delivering precision medicine to individuals
that takes into account genetic variants (SNP’s) that may predict response to a particular
medication and also may predict potential side effects. However, most pharmacogenomics
studies have taken place in populations of European descent, leaving out almost one in seven
Americans of African descent. The African American Cardiovascular Pharmacogenomic
Consortium Transdisciplinary Collaborative Center, also known as ACCOuNT , was established
to 1) discover novel genetic variants in African Americans related to clinically actionable
cardiovascular phenotypes, 2) incorporate African American specific SNPs into clinical
recommendations and 3) deliver this information to physicians at the point of care, so physicians
can make better informed decisions when prescribing cardiovascular medications for their
African American patients.
In order to achieve these aims, mechanisms need to be in place to 1) support implementation,
diffusion, and continuing evaluation and improvement of precision medicine in African
Americans under treatment for cardiovascular disease and 2) engage community leaders in
African American cardiovascular pharmacogenomic research. The ACCOuNT Consortium
Core will support these efforts.
The ACCOuNT Consortium Core will assume three essential roles that together will ensure
smooth, coordinated, and productive operations of our Transdiscplinary Collaborative Center
(TCC). First, it will provide a focal point for interactions among the several academic,
governmental, and community-based participants in this program. Second, it will facilitate
technical coordination among the academic health centers conducting the research proposed
here. Third, it will administer a pilot grant mechanism that stimulates new avenues of
collaboration among all participants, by funding pilot projects in conjunction with community
stakeholders.

## Key facts

- **NIH application ID:** 9934882
- **Project number:** 5U54MD010723-05
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** DAVID O MELTZER
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $68,803
- **Award type:** 5
- **Project period:** — → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9934882

## Citation

> US National Institutes of Health, RePORTER application 9934882, African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translation (5U54MD010723-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9934882. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*